SMASH-HCM Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions
- Coordinator
- Tampereen Korkeakoulusaatio Sr, Finland
- Runs
- 1 January 2024 to 31 December 2027
- Status
- Running
- EU funding
- €8.5m
- Total cost
- €8.5m
- Partners
- 17 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101137115
What the project is doing
In the project's own words, from its summary on CORDIS.
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular control, and, caused by HCM, ischemia, stroke, dementia, or psychological and social difficulties.
Multiple causal mutations and variations in cellular processes lead to highly diverse phenotypes and disease progression. However, HCM is still diagnosed as one single disease, leading to suboptimal care. SMASH-HCM will develop a digital-twin platform to dramatically improve HCM stratification and disease management, both for clinicians and patients. Multilevel and multiorgan dynamic biophysical and data-driven models are integrated in a three-level deep phenotyping approach designed for fast uptake into the clinical workflow.
SMASH-HCM unites 8 research partners, 3 hospitals, 3 SMEs, and a global health-technology corporation in collaboration with patients to advance the state of the art in human digital-twins: including in-vitro tools, in-silico from molecular to systemic level models, structured and unstructured data analysis, explainable artificial intelligence - all integrated into a decision support solution for both healthcare professionals and patients.
SMASH-HCM delivers new insights into HCM, improved patient care and guidance, validated preclinical tools, and above all, a first HCM stratification and management strategy, validated in a pilot clinical trial, and tested with end users. Thus providing a cost efficient and effective solution for this complex disease. SMASH-HCM develops a strategy towards fast regulatory approval. In reaching its goals, SMASH-HCM serves as a basis for future digital-twin platforms for other cardiac diseases integrating models and data from various scales and sources.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Tampereen Korkeakoulusaatio Sr | Tampere | Finland | Coordinator |
| Novamechanics Limited | Nicosia | Cyprus | Third party |
| Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh | Bonn | Germany | Participant |
| Universitaetsklinikum Hamburg-Eppendorf | Hamburg | Germany | Participant |
| Novamechanics Monoprosopi Ike | Piraeus | Greece | Participant |
| Centre Hospitalier Universitaire De Rennes | Rennes Cedex 9 | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Third party |
| Universite De Rennes | Rennes | France | Participant |
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Participant |
| Alma Mater Studiorum - Universita Di Bologna | Bologna | Italy | Participant |
| Azienda Ospedaliero-Universitaria Careggi | Firenze | Italy | Third party |
| Insilicotrials Technologies S.p.a. | Trieste | Italy | Participant |
| Politecnico Di Milano | Milano | Italy | Participant |
| Universita Degli Studi Di Firenze | Florence | Italy | Participant |
| Medtronic Bakken Research Center B.v. | Maastricht | Netherlands | Participant |
| Pharmatics Limited | Edinburgh | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI